Compare abrdn Income Credit Strategies Fund (ACP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs TransMedics Group Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while TransMedics Group Inc trades at $87.57 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 4.8× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ACP | TMDX | |
|---|---|---|
Market Cap | $641.16M | $3.10B |
Sector | Financials | Technology |
52-Week High | $5.98 | $150.42 |
52-Week Low | $5.01 | $61.99 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a net income margin of 95.31% and a low P/E of 7.74, though revenue declined to $42.46M in 2025 from $79M in 2024. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns.
The outlook is mixed: attractive valuation and high dividends offer income appeal, but revenue volatility and high leverage pose risks. Analyst sentiment is cautious due to unsustainable distribution rates and tight credit spreads, requiring careful monitoring of earnings and credit conditions for future performance.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
